A Phase 3 interventional study of Dutasteride 0.5mg capsules and Dutasteride placebo capsules in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Completed at 46 sites in 4 countries. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-04-05.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is one of 6 that started in 2014, is one of 11 in phase 3, and was the 16th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 45+
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Ankara Training and Research Hospital · Sites in Turkey
Ages 40–85 · Men only
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 40+ · Men only · Healthy volunteers
Il-Yang Pharm. Co., Ltd.
Ages 45+ · Men only
By country, each count listing its studies:
Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 607 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 118 across the 48 interventional studies. Of the 35 that completed or were terminated, 12 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 48 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Prostatic Hyperplasia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 17 (40%) have results posted.
Among the 43 studies in Prostatic Hyperplasia by GlaxoSmithKline, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 39th registered.
GlaxoSmithKline’s Prostatic Hyperplasia studies by the year they started, since 2003.
5 of the studies testing tamsulosin in Prostatic Hyperplasia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07870759Phase 3Il-Yang Pharm. Co., Ltd.Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia | 2027-08-31 |
| NCT07722884Ain Shams UniversityTamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH | 2027-01-01 |
| NCT07743034Mohsen PouraziziIris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07743060Mohsen PouraziziPupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, from their registry updates:
Among GlaxoSmithKline’s 43 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin monotherapy for the improvement of symptoms and health outcomes in an at risk population of benign prostatic hyperplasia (BPH) clinical progression including older men (>=50 years), with moderate-severe symptoms of BPH, enlarged prostates (>=30 cubicentimeter [cc]) and prostate specific antigen (PSA) >= 1.5 nanograms per milliliter (ng/mL). Each subject who met the eligibility criteria at screening will enter a four-week single-blind, placebo run-in period following which each subject will be randomised into a 2 year double-blind treatment phase. The total study duration for each subject will be up to 110 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any unstable, serious co-existing medical condition(s) including, but not limited to:
Current or Previous Use of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
Drug: Dutasteride 0.5mg capsules · Drug: Dutasteride placebo capsules · Drug: Tamsulosin 0.2mg tablets · Drug: Disintegrating placebo tamsulosin tablet
Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
Drug: Dutasteride placebo capsules · Drug: Tamsulosin 0.2mg tablets · Drug: Disintegrating placebo tamsulosin tablet
Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Commercially available tamsulosin 0.2mg tablets will be supplied.
Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months
IPSS (also called IPSS total score) is the sum of the seven questions with each score ranging from 0 (best) to 5 (worst). IPSS was self administered at screening, Baseline and each time-point of Month 3, 6, 9, 12, 15, 18, 21 and 24. Seven questions included are incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. The total IPSS score can range from 0-35 with severity catagories of mild (0 to 7), moderate (8 to 19) or severe (20 to 35). LOCF is defined as carrying forward the last non-missing post-Baseline assessment for participants with missing visit data and/or for participants who discontinued from the study. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Month 24 is the primary timepoint and earlier timepoints are considered secondary. Change from Baseline defined as difference between Post-Baseline value and Baseline value.
Time frame: Baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months
Percent Change in Prostate Volume From Baseline
Prostate Volume measurements were conducted annually using Transrectal ultrasound (TRUS). The following calculation was utilized to assess the prostate volume (cc): pi/6 (Anteroposterior Width multiplied by Cephalocaudal Width multiplied by Transverse Width). Post-Baseline prostate volume was calculated at 12 and 24 months. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value and reported as a percentage.
Time frame: Baseline,12 and 24 months
Number of Participants With IPSS Improvement From Baseline
Improvement in IPSS was categorized as improvement, no change and worsening. Improvement defined as greater than or equal to 2 points, greater than or equal to 3 points and greater than or equal to 25 percent in participants at months 3,6,9,12,15,18,21 and 24 . Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value.
Time frame: Baseline and 3, 6, 9,12,15,18,21 and 24 months
Change From Baseline in Maximum Urine Flow Rate (Qmax) by LOCF Approach
Qmax is defined as maximum urine flow. Qmax was measured with Uroflow meter (Urodyn 1000) at Screening, Baseline, and at Months 6,12,18 and 24. Change from Baseline Qmax at each scheduled post-Baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline Qmax. Baseline value was defined as the latest non-missing assessment either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline, 6, 12, 18 and 24 Months
Number of Participants With Qmax Improvement From Baseline by LOCF Approach.
Qmax change from Baseline was presented using six improvement levels: \>0 milliliter per second (mL/sec) and \>=1 mL/sec through \>=5mL/sec. Qmax percentage change from Baseline was presented using six improvement levels: \>0%, \>=10%, \>=20%, \>=30%, \>=40%, and \>=50%. Here, Qmax improvement of \>= 3 mL/sec and Qmax percentage of \>= 30 % for 24 Months has been summarized. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date.
Time frame: Baseline 6, 12, 18 and 24 Months
Number of Participants With Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery
AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization. AUR or BPH-related surgery event details per participant was summarized as first occurring of either AUR or BPH-related surgery.
Time frame: Up to 24 Months
Number of Subjects With AUR
AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization.
Time frame: Up to 24 Months
Number of Participants With BPH-related Surgery
BPH-related interventions were recorded. BPH-related interventions included adenomectomy, balloon dilatation, electroresection, thermotherapy (microwave or radiofrequency), laser resection, prostatectomy, prostatotomy, transurethral resection of the prostate, transurethral drainage of prostatic abscess, drainage of prostatic cysts, radioactive seeding of the prostate, prostatic urethral stenting, incision of periurethral stricture, ethanol injections into the prostate, transrectal high intensity focussed ultrasound, transurethral needle ablation and transurethral microwave thermotherapy.
Time frame: Up to 24 Months
Change From Baseline in the BPH-related Health Status (BHS) by LOCF Approach
BHS was collected as Question 8 the IPSS questionnaire regarding quality of life due to urinary symptom with scores values ranging from 0 (delightful) to 6 (terrible). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from baseline BHS at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BHS.
Time frame: Baseline, 3, 6, 9, 12, 15, 18, 21 and 24 Months
Change From Baseline in BPH Impact Index (BII) by LOCF Approach
The BII consists of four questions and BII total score is the sum of four questions. Total score range is 0 (no problem) to 13 (worst value). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline BII at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BII. Change from Baseline was summarized using LOCF approaches.
Time frame: Baseline 3, 6, 9, 12, 15, 18, 21 and 24 Months
Change From Baseline in Problem Assessment Scale of the Sexual Function Inventory (PAS-SFI)
PAS SFI consists of three questions each with a range of 0 (Big Problem) to 4 (No Problem). PAS SFI was administered at screening, Baseline and at each month 12 and 24. The total PSI is the sum of the three questions; the total score range is 0 to 12. Change from Baseline PAS SFI at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline PAS SFI. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline, 12 and 24 Months
Number of Hospitalization Days
Duration of hospitalization days due to AUR or BPH-related surgery was recorded.
Time frame: Up to 24 Months
Number of Participants in a Hospital Ward
Details of number of participants in different types of wards was recorded. Types of wards included general ward, recovery, intensive care unit, multiple ward types and others
Time frame: Up to 24 Months
Number of Participants With Hospital Admissions
Details of participants who were admitted to hospitals related to AUR or BPH-Related surgery has been recorded.
Time frame: Up to 24 Months
Number of Participants With Non-serious Adverse Events (AE) and Serious AE (SAE)
An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as resulting in death, life threatening, requires hospitalization or prolongation of hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation that is medically important, All events of possible drug-induced liver injury with hyperbilirubinaemia, male breast cancer and spontaneous abortion of a female partner of a male subject
Time frame: Up to 24 Months
Change From Baseline in Serum Prostate Specific Antigen (PSA)
Total serum PSA concentrations were assessed at pre-screening, month 6, 12 and 24. Change from baseline total PSA was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment at each scheduled post-baseline assessment using a general linear model with effects for treatment and baseline total PSA. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline 6, 12 and 24 Months
Number of Participants With Vital Signs Exceeding Threshold Values
Vital signs included assessment of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. Threshold ranges for SBP ranged from \< 80 mmHg (millimeter of mercury) (lower) to \> 165 mmHg (upper); for DBP ranged from \< 40 mmHg (lower) to \> 105 mmHg (upper) and heart rate \< 40 beats per minute (bpm) (lower) to \> 100 bpm (upper).
Time frame: Up to 24 Months
Change From Baseline in Post Void Residual Volume
Post void residual volume was measured suprapubically by ultrasound (immediately following the urinary flow measurement). Post void residual volume change from Baseline distribution at each scheduled post-Baseline assessment was compared with combination treatment (Dut plus Tam) versus tamsulosin treatment using a nonparametric van Elteren test. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline, 6, 12, 18 and 24 Months
Number of Participants With Threshold Hematology Value.
The threshold laboratory values are defined in terms of a multiplicative factor of the testing laboratory's normal range. A laboratory value that is above the upper limit factor multiplied by the upper limit of the normal (ULN) range is considered a high threshold value. A laboratory value that is below the lower limit factor multiplied by the lower limit of the normal (LLN) range is considered a low threshold value. Hematology laboratory parameters assessed included hemoglobin (Hgb), platelet count, white blood cell count (WBC) and red blood cell (RBC) count. Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to 24 Months
Number of Participants With Threshold Clinical Chemistry Value.
Clinical chemistry laboratory parameters assessed included albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatinine, glucose, potassium, sodium, total bilirubin, total protein and urea/blood urea nitrogen (BUN). Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to 24 Months
Number of Participants With Digital Rectal Examination (DRE)
DRE evaluation was carried out from normal/diffusely enlarged at Baseline to focal abnormalities at any time post-Baseline. DRE was assessed at screening visit, Month 6, 12, 18 , 24 and final assessment is the latest post-Baseline evaluation that was available. Here, participants with focal abnormalities are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: 6, 12, 18 , 24 months and final assessment
Number of Participants With Clinically Significant Qualitative Breast Examination
Qualitative breast examination included palpable breast tissue and nipple tenderness. Here, participants with clinically significant abnormalities for palpable breast tissue and nipple tenderness are summarized. Qualitative breast examination was done at screening visit, Month 6, 12, 18 , 24 and final assessment (latest post-Baseline evaluation that was available). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: 6, 12, 18 , 24 months and final assessment
Number of Participants With Suicidal Ideation and Suicidal Behavior
Suicidality was assessed utilizing the Columbia Suicide Severity Rating Scale (C-SSRS). It included tabular summaries of suicidal ideation and suicidal behavior questions that were administered. Assessments were carried out at Screening, Month 6, Month 12, and Month 24 (or end of treatment) visits. C-SSRS included Question1-2 were for suicidal ideation Question 1: Passive: wish to be dead, Question 2: Active: Non-specific (no method, intent or plan). Questions 6-10 were for suicidal behavior, Question 6: Preparatory Acts or Behavior, Question 7: any aborted attempt, Question 8: Any interrupted attempts, Question 9: Any non-fatal actual suicide attempt, Question 10: Completed suicide. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: 6, 12, 18 , 24 months and final assessment
A randomized, double-blind, parallel group trial to assess the effectiveness and safety of dutasteride (Dut) 0.5 milligram (mg) and tamsulosin (Tam) 0.2 mg combination compared to Tam 0.2 mg. The study consisted of a single-blind, placebo run-in, followed by a 2 year treatment. Eligible subjects were randomized to Dut + Tam or Dut placebo + Tam
| Milestone | Placebo +Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Started | 302 | 305 |
| Completed | 261 | 251 |
| Not completed | 41 | 54 |
| Withdrew: Adverse event | 15 | 20 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Protocol violation | 0 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Withdrawal by subject | 22 | 26 |
IPSS (also called IPSS total score) is the sum of the seven questions with each score ranging from 0 (best) to 5 (worst). IPSS was self administered at screening, Baseline and each time-point of Month 3, 6, 9, 12, 15, 18, 21 and 24. Seven questions included are incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. The total IPSS score can range from 0-35 with severity catagories of mild (0 to 7), moderate (8 to 19) or severe (20 to 35). LOCF is defined as carrying forward the last non-missing post-Baseline assessment for participants with missing visit data and/or for participants who discontinued from the study. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Month 24 is the primary timepoint and earlier timepoints are considered secondary. Change from Baseline defined as difference between Post-Baseline value and Baseline value.
| Score on scale | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 3, n=299, 296 | -4.07 ± 0.34 | -3.28 ± 0.34 |
| Month 6, n=300, 298 | -3.73 ± 0.37 | -3.36 ± 0.37 |
| Month 9, n=300, 298 | -4.14 ± 0.36 | -4.28 ± 0.36 |
| Month 12,n= 300, 298 | -3.93 ± 0.36 | -4.30 ± 0.36 |
| Month 15, n=300, 298 | -3.95 ± 0.36 | -4.90 ± 0.36 |
| Month 18, n=300, 298 | -3.84 ± 0.38 | -4.54 ± 0.38 |
| Month 21, n=300, 298 | -3.94 ± 0.38 | -4.66 ± 0.38 |
| Month 24, n=300, 298 | -3.53 ± 0.39 | -4.96 ± 0.39 |
Prostate Volume measurements were conducted annually using Transrectal ultrasound (TRUS). The following calculation was utilized to assess the prostate volume (cc): pi/6 (Anteroposterior Width multiplied by Cephalocaudal Width multiplied by Transverse Width). Post-Baseline prostate volume was calculated at 12 and 24 months. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value and reported as a percentage.
| Cubic centimeters (cc) | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 12, n=287, 286 | 0.2 ± 1.28 | -22.8 ± 0.99 |
| Month 24, n=287, 286 | 3.6 ± 1.45 | -24.8 ± 1.06 |
Improvement in IPSS was categorized as improvement, no change and worsening. Improvement defined as greater than or equal to 2 points, greater than or equal to 3 points and greater than or equal to 25 percent in participants at months 3,6,9,12,15,18,21 and 24 . Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline was reported based on the LOCF. Change from Baseline defined as difference between Post-Baseline value and Baseline value.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 3,>= 3 units, n=299, 296 | 160 | 157 |
| Month 3,>= 2 units, n=299,296 | 190 | 176 |
| Month 3,>= 25percent, n=299, 296 | 134 | 123 |
| Month 6,>= 3 units, n=300, 298 | 156 | 156 |
| Month 6,>= 2 units, n=300, 298 | 179 | 176 |
| Month 6,>= 25percent, n=300, 298 | 131 | 133 |
| Month 9,>= 3 units, n=300, 298 | 157 | 177 |
| Month 9,>= 2 units, n=300, 298 | 185 | 193 |
| Month 9,>= 25percent, n=300, 298 | 128 | 150 |
| Month 12,>= 3 units, n=300, 298 | 154 | 171 |
| Month 12,>= 2 units, n=300, 298 | 179 | 191 |
| Month 12,>= 25percent, n=300, 298 | 131 | 154 |
| Month 15,>= 3 units, n=300, 298 | 171 | 186 |
| Month 15,>= 2 units, n=300, 298 | 186 | 203 |
| Month 15,>= 25percent, n=300, 298 | 133 | 160 |
| Month 18,>= 3 units, n=300, 298 | 156 | 171 |
| Month 18,>= 2 units, n=300, 298 | 173 | 187 |
| Month 18,>= 25percent, n=300, 298 | 136 | 148 |
| Month 21,>= 3 units, n=300, 298 | 169 | 178 |
| Month 21,>= 2 units, n=300, 298 | 186 | 194 |
| Month 21,>= 25percent, n=300, 298 | 141 | 161 |
| Month 24,>= 3 units, n=300, 298 | 156 | 184 |
| Month 24,>= 2 units, n=300, 298 | 175 | 197 |
| Month 24,>= 25percent, n=300, 298 | 137 | 169 |
Qmax is defined as maximum urine flow. Qmax was measured with Uroflow meter (Urodyn 1000) at Screening, Baseline, and at Months 6,12,18 and 24. Change from Baseline Qmax at each scheduled post-Baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline Qmax. Baseline value was defined as the latest non-missing assessment either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| milliliter per second (mL/sec) | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 6, n=270, 274 | 0.62 ± 0.26 | 1.54 ± 0.26 |
| Month 12, n=286, 287 | 0.63 ± 0.28 | 1.62 ± 0.27 |
| Month 18, n=287, 288 | 0.90 ± 0.33 | 2.36 ± 0.33 |
| Month 24, n=287,290 | 0.93 ± 0.32 | 2.27 ± 0.32 |
Qmax change from Baseline was presented using six improvement levels: \>0 milliliter per second (mL/sec) and \>=1 mL/sec through \>=5mL/sec. Qmax percentage change from Baseline was presented using six improvement levels: \>0%, \>=10%, \>=20%, \>=30%, \>=40%, and \>=50%. Here, Qmax improvement of \>= 3 mL/sec and Qmax percentage of \>= 30 % for 24 Months has been summarized. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Baseline value is defined as the latest non-missing assessment of either treatment start date or randomization date.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 6, >= 3 mL/sec, n=270, 274 | 69 | 86 |
| Month 6, >= 3 %, n=270, 274 | 70 | 86 |
| Month 12, >= 3 mL/sec, n=286, 287 | 64 | 102 |
| Month 12, >= 3 %, n=286, 287 | 73 | 107 |
| Month 18, >= 3 mL/sec, n=287, 288 | 80 | 115 |
| Month 18, >= 3 %, n= 287, 288 | 81 | 111 |
| Month 24, >= 3 mL/sec, n=287, 290 | 77 | 121 |
| Month 24, >= 30 %, n=287, 290 | 71 | 119 |
AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization. AUR or BPH-related surgery event details per participant was summarized as first occurring of either AUR or BPH-related surgery.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Overall | 15 | 4 |
| Year 1 subset | 8 | 2 |
| Year 2 subset | 7 | 2 |
AUR is defined as condition when the participant is unable to urinate and requires bladder catheterization.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Overall | 13 | 2 |
| Year 1 subset | 8 | 2 |
| Year 2 subset | 5 | 0 |
BPH-related interventions were recorded. BPH-related interventions included adenomectomy, balloon dilatation, electroresection, thermotherapy (microwave or radiofrequency), laser resection, prostatectomy, prostatotomy, transurethral resection of the prostate, transurethral drainage of prostatic abscess, drainage of prostatic cysts, radioactive seeding of the prostate, prostatic urethral stenting, incision of periurethral stricture, ethanol injections into the prostate, transrectal high intensity focussed ultrasound, transurethral needle ablation and transurethral microwave thermotherapy.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Overall | 3 | 2 |
| Year 1 subset | 0 | 0 |
| Year 2 subset | 3 | 2 |
BHS was collected as Question 8 the IPSS questionnaire regarding quality of life due to urinary symptom with scores values ranging from 0 (delightful) to 6 (terrible). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from baseline BHS at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BHS.
| Scores on scale | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 3, n=299, 296 | -0.88 ± 0.08 | -0.85 ± 0.08 |
| Month 6, n=300,298 | -0.89 ± 0.08 | -0.73 ± 0.08 |
| Month 9, n=300, 298 | -1.08 ± 0.08 | -0.95 ± 0.08 |
| Month 12, n=300, 298 | -0.87 ± 0.08 | -0.90 ± 0.08 |
| Month 15, n=300, 298 | -0.93 ± 0.08 | -1.02 ± 0.08 |
| Month 18, n=300, 298 | -0.92 ± 0.08 | -1.00 ± 0.08 |
| Month 21, n=300, 298 | -1.08 ± 0.09 | -1.02 ± 0.09 |
| Month 24, n=300, 298 | -1.00 ± 0.08 | -1.16 ± 0.08 |
The BII consists of four questions and BII total score is the sum of four questions. Total score range is 0 (no problem) to 13 (worst value). Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline BII at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline BII. Change from Baseline was summarized using LOCF approaches.
| Scores on scale | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 3, n=299, 296 | -1.48 ± 0.14 | -1.23 ± 0.14 |
| Month 6, n=300, 298 | -1.28 ± 0.15 | -1.08 ± 0.16 |
| Month 9, n=300, 298 | -1.55 ± 0.15 | -1.26 ± 0.16 |
| Month 12, n=300, 298 | -1.39 ± 0.16 | -1.24 ± 0.16 |
| Month 15, n=300, 298 | -1.30 ± 0.16 | -1.41 ± 0.16 |
| Month 18, n=300, 298 | -1.16 ± 0.16 | -1.28 ± 0.16 |
| Month 21, n=300, 298 | -1.12 ± 0.17 | -1.27 ± 0.17 |
| Month 24, n=300, 298 | -1.02 ± 0.17 | -1.48 ± 0.17 |
PAS SFI consists of three questions each with a range of 0 (Big Problem) to 4 (No Problem). PAS SFI was administered at screening, Baseline and at each month 12 and 24. The total PSI is the sum of the three questions; the total score range is 0 to 12. Change from Baseline PAS SFI at each scheduled post-baseline assessment was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment using t-tests from a general linear model with effects for treatment, country, and Baseline PAS SFI. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Scores on scale | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 12, n=291, 293 | 0.11 ± 0.21 | -0.91 ± 0.20 |
| Month 24, n=291, 294 | -0.11 ± 0.21 | -0.82 ± 0.21 |
Duration of hospitalization days due to AUR or BPH-related surgery was recorded.
| Days | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Number of Hospitalization Days | 10.0 (6 to 18) | 9.0 (7 to 12) |
Details of number of participants in different types of wards was recorded. Types of wards included general ward, recovery, intensive care unit, multiple ward types and others
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| General ward | 2 | 0 |
| Recovery | 0 | 1 |
| Other | 1 | 0 |
Details of participants who were admitted to hospitals related to AUR or BPH-Related surgery has been recorded.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Out-patient | 5 | 0 |
| In-patient | 6 | 3 |
An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as resulting in death, life threatening, requires hospitalization or prolongation of hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation that is medically important, All events of possible drug-induced liver injury with hyperbilirubinaemia, male breast cancer and spontaneous abortion of a female partner of a male subject
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Any Non-serious AE | 203 | 208 |
| Any SAE | 52 | 49 |
Total serum PSA concentrations were assessed at pre-screening, month 6, 12 and 24. Change from baseline total PSA was compared in terms of combination treatment (Dut plus Tam) versus tamsulosin treatment at each scheduled post-baseline assessment using a general linear model with effects for treatment and baseline total PSA. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| nanogram/milliliter (ng/mL) | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 6, n=292, 294 | 0.2 ± 0.09 | -1.7 ± 0.08 |
| Month 12, n=293, 294 | 0.2 ± 0.08 | -1.9 ± 0.08 |
| Month 24, n=293, 295 | 0.7 ± 0.16 | -2.0 ± 0.16 |
Vital signs included assessment of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. Threshold ranges for SBP ranged from \< 80 mmHg (millimeter of mercury) (lower) to \> 165 mmHg (upper); for DBP ranged from \< 40 mmHg (lower) to \> 105 mmHg (upper) and heart rate \< 40 beats per minute (bpm) (lower) to \> 100 bpm (upper).
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| SBP, < 80 mmHg | 0 | 0 |
| SBP, > 165 mmHg | 10 | 13 |
| SBP, either threshold | 10 | 13 |
| DBP, < 40 mmHg | 0 | 0 |
| DBP, > 105 mmHg | 6 | 2 |
| DBP, either threshold | 6 | 2 |
| Heart rate, < 40 bpm | 0 | 0 |
| Heart rate, > 100 bpm | 11 | 14 |
| Heart rate, either threshold | 11 | 14 |
Post void residual volume was measured suprapubically by ultrasound (immediately following the urinary flow measurement). Post void residual volume change from Baseline distribution at each scheduled post-Baseline assessment was compared with combination treatment (Dut plus Tam) versus tamsulosin treatment using a nonparametric van Elteren test. Baseline value was defined as the latest non-missing assessment of either treatment start date or randomization date. Change from Baseline defined as difference between Post-Baseline value and Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| mL | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 6, n=288, 290 | -4.8 ± 52.59 | -3.0 ± 59.56 |
| Month 12, n=291, 292 | 1.5 ± 60.94 | -1.4 ± 59.19 |
| Month 18, n=291, 292 | -2.6 ± 55.67 | -1.3 ± 63.98 |
| Month 24, n=291, 292 | 2.6 ± 64.71 | -2.6 ± 62.01 |
The threshold laboratory values are defined in terms of a multiplicative factor of the testing laboratory's normal range. A laboratory value that is above the upper limit factor multiplied by the upper limit of the normal (ULN) range is considered a high threshold value. A laboratory value that is below the lower limit factor multiplied by the lower limit of the normal (LLN) range is considered a low threshold value. Hematology laboratory parameters assessed included hemoglobin (Hgb), platelet count, white blood cell count (WBC) and red blood cell (RBC) count. Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Hgb, <0.75 X LLN, n=287, 291 | 0 | 0 |
| Platelet count, <0.75 X LLN, n=284, 283 | 6 | 1 |
| Platelet count, >1.50 X ULN, n=285, 285 | 0 | 0 |
| RBC, <0.50 X LLN, n=287, 291 | 0 | 0 |
| WBC, <0.50 X LLN, n=287, 291 | 0 | 0 |
| WBC, >3.00 X ULN, n=287, 291 | 0 | 0 |
Clinical chemistry laboratory parameters assessed included albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatinine, glucose, potassium, sodium, total bilirubin, total protein and urea/blood urea nitrogen (BUN). Threshold factors are in the below table. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| albumin, <0.90 X LLN, n=289, 292 | 0 | 0 |
| albumin, >1.20 X ULN, n=289, 292 | 0 | 0 |
| ALT, >3.00 X ULN, n=289, 292 | 0 | 0 |
| ALP, > 1.50 X ULN, n=289, 292 | 0 | 0 |
| AST, >3.00 X ULN, n=288, 292 | 0 | 1 |
| creatinine, <0.50 X LLN, n=289, 292 | 0 | 0 |
| creatinine, >3.00 X ULN, n=289, 292 | 0 | 0 |
| glucose, <0.70 X LLN, n=288, 292 | 0 | 0 |
| glucose, >1.75 X ULN, n=280, 285 | 13 | 13 |
| potassium, <0.75 X LLN, n=288, 292 | 0 | 0 |
| potassium, >1.40 X ULN, n=288, 292 | 0 | 0 |
| sodium, <0.90 X LLN, n=289, 292 | 0 | 0 |
| sodium, >1.15 X ULN, n=289, 292 | 0 | 0 |
| total bilirubin, >2.50 X ULN, n=289, 292 | 0 | 0 |
| total protein, <0.80 X LLN, n=289, 292 | 0 | 0 |
| total protein, >1.15 X ULN, n=289, 292 | 0 | 0 |
| Urea/BUN, <0.50 X LLN, n=289, 292 | 0 | 0 |
| Urea/BUN, >2.00 X ULN, n=289, 292 | 0 | 0 |
DRE evaluation was carried out from normal/diffusely enlarged at Baseline to focal abnormalities at any time post-Baseline. DRE was assessed at screening visit, Month 6, 12, 18 , 24 and final assessment is the latest post-Baseline evaluation that was available. Here, participants with focal abnormalities are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 6, n=287, 285 | 11 | 9 |
| Month 12, n=279, 272 | 10 | 11 |
| Month 18, n=267, 258 | 6 | 12 |
| Month 24, n=261, 252 | 10 | 13 |
| Final Assessment, n=296, 295 | 10 | 15 |
Qualitative breast examination included palpable breast tissue and nipple tenderness. Here, participants with clinically significant abnormalities for palpable breast tissue and nipple tenderness are summarized. Qualitative breast examination was done at screening visit, Month 6, 12, 18 , 24 and final assessment (latest post-Baseline evaluation that was available). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Palpable breast tissue, Month 6, n=289, 284 | 0 | 0 |
| Nipple tenderness,Month 6, n=289, 284 | 0 | 0 |
| Palpable breast tissue, Month 12, n=279, 273 | 1 | 2 |
| Nipple tenderness,Month 12, n=279, 273 | 0 | 1 |
| Palpable breast tissue, Month 18, n=267, 258 | 1 | 0 |
| Nipple tenderness,Month 18, n=267, 258 | 0 | 0 |
| Palpable breast tissue, Month 24, n=262, 252 | 0 | 0 |
| Nipple tenderness, Month 24, n=262, 252 | 0 | 0 |
| Palpable breast tissue,final assessment, n=296,296 | 0 | 0 |
| Nipple tenderness,final assessment, n=296, 296 | 0 | 0 |
Suicidality was assessed utilizing the Columbia Suicide Severity Rating Scale (C-SSRS). It included tabular summaries of suicidal ideation and suicidal behavior questions that were administered. Assessments were carried out at Screening, Month 6, Month 12, and Month 24 (or end of treatment) visits. C-SSRS included Question1-2 were for suicidal ideation Question 1: Passive: wish to be dead, Question 2: Active: Non-specific (no method, intent or plan). Questions 6-10 were for suicidal behavior, Question 6: Preparatory Acts or Behavior, Question 7: any aborted attempt, Question 8: Any interrupted attempts, Question 9: Any non-fatal actual suicide attempt, Question 10: Completed suicide. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Month 6, Suicidal ideation, Q1, n=289, 285 | 0 | 0 |
| Month 6, Suicidal ideation, Q2, n=289, 285 | 0 | 0 |
| Month 6, Suicidal behavior, Q6, n=289, 285 | 0 | 0 |
| Month 6, Suicidal behavior, Q7, n=289, 285 | 0 | 0 |
| Month 6, Suicidal behavior, Q8, n=289, 285 | 0 | 0 |
| Month 6, Suicidal behavior, Q9, n=289, 285 | 0 | 0 |
| Month 6, Suicidal behavior, Q10, n=289, 285 | 0 | 0 |
| Month 12, Suicidal ideation, Q1, n=279, 273 | 0 | 0 |
| Month 12, Suicidal ideation, Q2, n=279, 273 | 0 | 0 |
| Month 12, Suicidal behavior, Q6, n=279, 273 | 0 | 0 |
| Month 12, Suicidal behavior, Q7, n=279, 273 | 0 | 0 |
| Month 12, Suicidal behavior, Q8, n=279, 273 | 0 | 0 |
| Month 12, Suicidal behavior, Q9, n=279, 273 | 0 | 0 |
| Month 12, Suicidal behavior, Q10, n=279, 273 | 0 | 0 |
| Month 24, Suicidal ideation, Q1, n=261, 251 | 0 | 1 |
| Month 24, Suicidal ideation, Q2, n=261, 251 | 0 | 0 |
| Month 12, Suicidal behavior, Q6, n=261, 251 | 0 | 0 |
| Month 12, Suicidal behavior, Q7, n=261, 251 | 0 | 0 |
| Month 12, Suicidal behavior, Q8, n=261, 251 | 0 | 0 |
| Month 12, Suicidal behavior, Q9, n=261, 251 | 0 | 0 |
| Month 12, Suicidal behavior, Q10, n=261, 251 | 0 | 0 |
| Final assessment, Suicidal ideation,Q1, n=288, 285 | 0 | 1 |
| Final assessment, Suicidal ideation,Q2, n=288, 285 | 0 | 0 |
| Final assessment, Suicidal behavior,Q6, n=288, 285 | 0 | 0 |
| Final assessment, Suicidal behavior,Q7, n=288, 285 | 0 | 0 |
| Final assessment, Suicidal behavior,Q8, n=288, 285 | 0 | 0 |
| Final assessment, Suicidal behavior,Q9, n=288, 285 | 0 | 0 |
| Final assessment, Suicidal behavior,Q10,n=288, 285 | 0 | 0 |
Collected over Up to 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Tam 0.2mg | 1/302 (0.3%) | 52/302 (17.2%) | 203/302 (67.2%) |
| Dut 0.5 mg + Tam 0.2 mg | 2/305 (0.7%) | 49/305 (16.1%) | 208/305 (68.2%) |
| Event | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Large intestine polypGastrointestinal disorders | 7/302 | 0/305 |
| Inguinal herniaGastrointestinal disorders | 5/302 | 2/305 |
| Arteriosclerosis coronary arteryCardiac disorders | 2/302 | 3/305 |
| HaemorrhoidsGastrointestinal disorders | 2/302 | 0/305 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/302 | 0/305 |
| Cerebral infarctionNervous system disorders | 2/302 | 0/305 |
| BronchitisInfections and infestations | 2/302 | 0/305 |
| CataractEye disorders | 2/302 | 0/305 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 2/302 | 0/305 |
| SyncopeNervous system disorders | 1/302 | 2/305 |
| Event | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 38/302 | 24/305 |
| NasopharyngitisInfections and infestations | 30/302 | 37/305 |
| DizzinessNervous system disorders | 16/302 | 14/305 |
| Back painMusculoskeletal and connective tissue disorders | 11/302 | 14/305 |
| Erectile dysfunctionReproductive system and breast disorders | 3/302 | 14/305 |
| ConstipationGastrointestinal disorders | 3/302 | 13/305 |
| BronchitisInfections and infestations | 11/302 | 8/305 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 11/302 | 7/305 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/302 | 7/305 |
| EczemaSkin and subcutaneous tissue disorders | 5/302 | 11/305 |
Intent-to-Treat Population, comprised of all randomized participants who received or did not receive study treatment
| Age, Continuous(Years) | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg | Total |
|---|---|---|---|
| Mean | 66.2 ± 6.85 | 66.8 ± 6.82 | 66.5 ± 6.84 |
| Sex: Female, Male(Participants) | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 302 | 305 | 607 |
| Race/Ethnicity, Customized(Participants) | Placebo + Tam 0.2mg | Dut 0.5 mg + Tam 0.2 mg | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 234 | 236 | 470 |
| Asian - Japanese Heritage | 68 | 67 | 135 |
| Asian - Southeast Asian Heritage | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Feb 2014 to primary completion in Mar 2017, 36 months.
Results were first posted in Apr 2019, 2 years 1 month after primary completion.
Of 17 phase 3 interventional studies under Prostatic Hyperplasia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin